Enzymlogic
I+D hoy
Enzymlogic is a contract research organization that represents scientific excellence in enzymology and binding kinetics analysis for small molecule drug discovery programmes.
Enzymlogic accelerates and improves the research productivity and effectiveness of its customer screening, lead optimization, Structure-Activity Relationship (SAR) and Structure-Kinetic Relationship (SKR) campaigns by its expertise and unique methodology for the discovery and development of new drugs.
We offer innovative services such as the characterization of drug-target binding kinetics, the assessment of drug-target kinetic selectivity or the determination of drug-target binding mechanism to encourage the identification of inhibitors with novel modes of binding and enhanced clinical efficiency. We also apply enzymatic mechanistic principles to assay design in order to provide high-quality biochemical assays and increase the pharmacological diversity of selected compounds.
Our services can notably improve decision-making, yielding compounds with higher development potential and reduced risk of failure.
*Binding Kinetics: compounds with similar affinity for a given target can exhibit different clinical efficiency due to variations in their kinetic profiles. Our proprietary method allows the rapid identification of compounds with the desired kinetic parameters as an efficient starting point for lead development and the parallel optimization of binding affinity (SAR) and binding kinetics (SKR).
*Kinetic selectivity: Enzymlogic provides a complete picture of the in vivo behavior of your drugs. Selectivity is highly dynamic in human body and evolves over the course of treatment as a function of the temporal binding between the drug and the main and secondary targets. Over the course of dosing, a drug showing a prolonged interaction with its main target and shorten interactions with secondary targets exhibits temporal target selectivity. Safety and tolerability will considerably improve if the intrinsic toxicity of the drug is minimal. In contrast, a drug that display a sustained interaction with a secondary toxicity-mediating target will result in safety issues.
*Binding mechanism: high-affinity interactions often entail conformational rearrangements originated by structural changes at the drug-target binding site. Enzymlogic provides structural information in the early stages of drug discovery.
*Assay Development: we apply enzymatic mechanistic principles to assay design in order to encourage the identification of inhibitors with novel modes of binding.
I+D hoy
Enzymlogic is a contract research organization that represents scientific excellence in enzymology and binding kinetics analysis for small molecule drug discovery programmes.
Enzymlogic accelerates and improves the research productivity and effectiveness of its customer screening, lead optimization, Structure-Activity Relationship (SAR) and Structure-Kinetic Relationship (SKR) campaigns by its expertise and unique methodology for the discovery and development of new drugs.
We offer innovative services such as the characterization of drug-target binding kinetics, the assessment of drug-target kinetic selectivity or the determination of drug-target binding mechanism to encourage the identification of inhibitors with novel modes of binding and enhanced clinical efficiency. We also apply enzymatic mechanistic principles to assay design in order to provide high-quality biochemical assays and increase the pharmacological diversity of selected compounds.
Our services can notably improve decision-making, yielding compounds with higher development potential and reduced risk of failure.
*Binding Kinetics: compounds with similar affinity for a given target can exhibit different clinical efficiency due to variations in their kinetic profiles. Our proprietary method allows the rapid identification of compounds with the desired kinetic parameters as an efficient starting point for lead development and the parallel optimization of binding affinity (SAR) and binding kinetics (SKR).
*Kinetic selectivity: Enzymlogic provides a complete picture of the in vivo behavior of your drugs. Selectivity is highly dynamic in human body and evolves over the course of treatment as a function of the temporal binding between the drug and the main and secondary targets. Over the course of dosing, a drug showing a prolonged interaction with its main target and shorten interactions with secondary targets exhibits temporal target selectivity. Safety and tolerability will considerably improve if the intrinsic toxicity of the drug is minimal. In contrast, a drug that display a sustained interaction with a secondary toxicity-mediating target will result in safety issues.
*Binding mechanism: high-affinity interactions often entail conformational rearrangements originated by structural changes at the drug-target binding site. Enzymlogic provides structural information in the early stages of drug discovery.
*Assay Development: we apply enzymatic mechanistic principles to assay design in order to encourage the identification of inhibitors with novel modes of binding.